189 related articles for article (PubMed ID: 22892077)
1. [Gaucher disease in Latin America. A report from the Gaucher Disease International Registry and the Latin American Group for Gaucher Disease].
Drelichman G; Linares A; Villalobos J; Cabello JF; Kerstenetzky M; Kohan RM; Martins AM
Medicina (B Aires); 2012; 72(4):273-82. PubMed ID: 22892077
[TBL] [Abstract][Full Text] [Related]
2. Baseline characteristics of 32 patients with Gaucher disease who were treated with imiglucerase: South African data from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
Sevittz H; Laher F; Varughese ST; Nel M; McMaster A; Jacobson BF
S Afr Med J; 2022 Feb; 112(1):13518. PubMed ID: 35140000
[TBL] [Abstract][Full Text] [Related]
3. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
[TBL] [Abstract][Full Text] [Related]
4. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.
Andersson H; Kaplan P; Kacena K; Yee J
Pediatrics; 2008 Dec; 122(6):1182-90. PubMed ID: 19047232
[TBL] [Abstract][Full Text] [Related]
5. [Gaucher disease: A review].
Nguyen Y; Stirnemann J; Belmatoug N
Rev Med Interne; 2019 May; 40(5):313-322. PubMed ID: 30638965
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years.
Hollak CE; Belmatoug N; Cole JA; Vom Dahl S; Deegan PB; Goldblatt J; Rosenbloom B; van Dussen L; Tylki-Szymańska A; Weinreb NJ; Zimran A; Cappellini MD
Br J Haematol; 2012 Aug; 158(4):528-38. PubMed ID: 22640238
[TBL] [Abstract][Full Text] [Related]
7. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
Wenstrup RJ; Kacena KA; Kaplan P; Pastores GM; Prakash-Cheng A; Zimran A; Hangartner TN
J Bone Miner Res; 2007 Jan; 22(1):119-26. PubMed ID: 17032149
[TBL] [Abstract][Full Text] [Related]
8. Gaucher Disease: Clinical, Biological and Therapeutic Aspects.
Dandana A; Ben Khelifa S; Chahed H; Miled A; Ferchichi S
Pathobiology; 2016; 83(1):13-23. PubMed ID: 26588331
[TBL] [Abstract][Full Text] [Related]
9. [Gaucher disease: importance of early diagnosis and therapy].
Simon G; Erdos M; Maródi L; Tóth J
Orv Hetil; 2008 Apr; 149(16):743-50. PubMed ID: 18426721
[TBL] [Abstract][Full Text] [Related]
10. The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause).
Zimran A; Morris E; Mengel E; Kaplan P; Belmatoug N; Hughes DA; Malinova V; Heitner R; Sobreira E; Mrsić M; Granovsky-Grisaru S; Amato D; vom Dahl S
Blood Cells Mol Dis; 2009; 43(3):264-88. PubMed ID: 19502088
[TBL] [Abstract][Full Text] [Related]
11. Velaglucerase alfa for the management of type 1 Gaucher disease.
Morris JL
Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
[TBL] [Abstract][Full Text] [Related]
12. Long-term bone outcomes in Italian patients with Gaucher disease type 1 or type 3 treated with imiglucerase: A sub-study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
Cappellini MD; Carubbi F; Di Rocco M; Giona F; Giuffrida G
Blood Cells Mol Dis; 2023 Jan; 98():102705. PubMed ID: 36327675
[TBL] [Abstract][Full Text] [Related]
13. Gaucher disease.
Mignot C; Gelot A; De Villemeur TB
Handb Clin Neurol; 2013; 113():1709-15. PubMed ID: 23622393
[TBL] [Abstract][Full Text] [Related]
14. [Gaucher Disease].
Okuyama T
Brain Nerve; 2015 Sep; 67(9):1109-13. PubMed ID: 26329151
[TBL] [Abstract][Full Text] [Related]
15. Management of Gaucher disease in a post-communist transitional health care system: Croatian experience.
Mrsić M; Stavljenić-Rukavina A; Fumić K; Labar B; Bogdanić V; Potocki K; Kardum-Skelin I; Rovers D
Croat Med J; 2003 Oct; 44(5):606-9. PubMed ID: 14515422
[TBL] [Abstract][Full Text] [Related]
16. Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease.
Hollak CE; vom Dahl S; Aerts JM; Belmatoug N; Bembi B; Cohen Y; Collin-Histed T; Deegan P; van Dussen L; Giraldo P; Mengel E; Michelakakis H; Manuel J; Hrebicek M; Parini R; Reinke J; di Rocco M; Pocovi M; Sa Miranda MC; Tylki-Szymanska A; Zimran A; Cox TM
Blood Cells Mol Dis; 2010 Jan; 44(1):41-7. PubMed ID: 19804996
[TBL] [Abstract][Full Text] [Related]
17. Pediatric Gaucher experience in South Marmara region of Turkey.
Erdemır G; Özkan T; Özgür T; Yazici Z; Özdemır Ö
Turk J Gastroenterol; 2011 Oct; 22(5):500-4. PubMed ID: 22234757
[TBL] [Abstract][Full Text] [Related]
18. Baseline characteristics and outcome in Romanian patients with Gaucher disease type 1.
Grigorescu-Sido P; Drugan C; Alkhzouz C; Zimmermann A; Coldea C; Denes C; Grigorescu MD; Cret V; Bucerzan S
Eur J Intern Med; 2010 Apr; 21(2):104-13. PubMed ID: 20206881
[TBL] [Abstract][Full Text] [Related]
19. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis.
Kaplan P; Andersson HC; Kacena KA; Yee JD
Arch Pediatr Adolesc Med; 2006 Jun; 160(6):603-8. PubMed ID: 16754822
[TBL] [Abstract][Full Text] [Related]
20. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
Heitner R; Arndt S; Levin JB
S Afr Med J; 2004 Aug; 94(8):647-51. PubMed ID: 15352589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
